Allscripts Healthcare Can Gain Market Share, Jefferies & Company Reports

In a report released this morning, Jefferies & Company is reiterating its Buy rating on shares of Allscripts Healthcare MDRX. “As expected, guidance was slightly below forecasts,” Jefferies & Company writes. “We remain steadfast MDRX can gain market share in the physician market and increasingly up-sell the Eclipsys hospital client base.” Jefferies & Company maintains its $1.456B revenue estimate and $0.91 adjusted EPS estimate. Allscripts Healthcare currently trades at $19.36.